Block Listing Interim Review
Allergy Therapeutics plc
("Allergy Therapeutics", "ATL" or the "Group")
Block Listing Interim Review
Name of applicant: | ALLERGY THERAPEUTICS PLC | |||
Name of scheme: | Allergy Therapeutics plc 2013 Long Term Incentive Plan | |||
Period of return: | From: | 1 October 2023 | To: | 17 December 2024 |
Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission: | 10,000,000 ordinary shares of 0.1p each in the Company admitted to trading on 24 November 2017 Additional listing of 7,000,000 ordinary shares of 0.1p each in the Company admitted to trading on 7 April 2021 Additional listing of 5,000,000 ordinary shares of 0.1p each in the Company admitted to trading on 3 October 2023
| |||
Balance of unallotted securities under scheme(s) from previous return: | 12,013,147 ordinary shares | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | ||||
Less: Number of securities issued/allotted under scheme(s) during period: | 12,013,147 ordinary shares of 0.1p each | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | Nil | |||
Name of contact: | Karley Cheesman |
Telephone number of contact: | +44 (0) 1903 844 700 |
For further information, please contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive Officer
Shaun Furlong, Chief Financial Officer
+44 (0)1903 845 820
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash /Giles Balleny/ Seamus Fricker / Rory Sale
Nigel Birks - Life Science Specialist Sales
Tamar Cranford Smith - Sales
+44 (0)20 7220 0500
ICR Healthcare
Mary-Jane Elliott / David Daley / Davide Salvi
+44 (0)20 3709 5700
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more information, please see www.allergytherapeutics.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.